JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $72 to $76.
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $72 to $76.